Urinary Tract Infection (Adult)

1. Topic Overview

Summary

Urinary tract infection (UTI) represents one of the most prevalent bacterial infections worldwide, accounting for approximately 150 million cases annually and significant healthcare expenditure. [1] UTIs are classified anatomically as lower (cystitis, urethritis) or upper (pyelonephritis, renal abscess) and clinically as uncomplicated or complicated. Escherichia coli causes 75-95% of community-acquired UTIs, with other uropathogens including Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus, and Enterococcus species. [2]

Uncomplicated cystitis in non-pregnant women can be diagnosed clinically and treated empirically with short-course antibiotics (3-5 days nitrofurantoin, trimethoprim, or fosfomycin). Pyelonephritis requires longer treatment duration (7-14 days) and may necessitate hospitalization for intravenous therapy if severe. [3] Men with UTI, pregnant women, patients with urological abnormalities, immunocompromised hosts, and those with catheter-associated infections require specialized evaluation and management approaches.

Antimicrobial resistance in uropathogens is an escalating global health threat, with increasing rates of extended-spectrum beta-lactamase (ESBL)-producing organisms and fluoroquinolone resistance. [4] Appropriate empirical therapy selection, antimicrobial stewardship, and strategies to prevent recurrent infections are essential components of contemporary UTI management.

Key Facts

• Global Burden: 150 million UTI cases annually worldwide; second most common bacterial infection after respiratory tract infections [1]
• Causative Organism: E. coli accounts for 75-95% of community-acquired UTIs, 50-70% of healthcare-associated UTIs [2]
• Gender Disparity: 50-60% of women experience at least one UTI in their lifetime; male incidence increases after age 50 due to prostatic hypertrophy [5]
• Recurrence Rate: 25-30% of women experience recurrent UTI within 6 months of initial episode; 44-50% within 12 months [6]
• Uncomplicated Cystitis: Nitrofurantoin 100mg modified-release BD for 3 days OR trimethoprim 200mg BD for 3 days (first-line if local resistance less than 20%) [3]
• Pyelonephritis: Ciprofloxacin 500mg BD for 7 days (mild outpatient) OR IV ceftriaxone/co-amoxiclav (severe, requiring hospitalization) [3]
• Pregnancy: Treat asymptomatic bacteriuria (screen at 12-16 weeks); untreated ASB leads to pyelonephritis in 20-40% [7]
• Antimicrobial Resistance: ESBL-producing E. coli prevalence 10-15% in community, 20-30% in healthcare settings; fluoroquinolone resistance 15-30% [4]

Clinical Pearls

"Lower vs Upper UTI Distinction is Critical": Dysuria, frequency, urgency without fever = cystitis (outpatient management). Fever ≥38°C + loin pain + systemic symptoms = pyelonephritis (consider admission, IV antibiotics, imaging). Distinguishing these presentations guides appropriate treatment intensity and setting.

"All Men with UTI Require Investigation": UTI in males is complicated by definition due to longer urethra and anatomical protection. Investigate for prostatic disease (BPH, prostatitis, cancer), urolithiasis, urethral stricture, or immunosuppression. First UTI in a man warrants renal tract imaging.

"Treat Asymptomatic Bacteriuria Only in Pregnancy and Pre-Urological Procedures": Asymptomatic bacteriuria (ASB) is common in elderly, catheterized, and diabetic patients but does not require treatment except in pregnancy (prevents pyelonephritis, preterm labor) and before urological instrumentation. Unnecessary ASB treatment drives antimicrobial resistance. [8]

"Urine Culture Before Antibiotics in Recurrent, Complicated, or Failed Treatment": While uncomplicated cystitis can be treated empirically, obtain midstream urine (MSU) culture before antibiotics in: recurrent UTI, men, pregnancy, suspected pyelonephritis, catheterized patients, immunocompromised hosts, or treatment failure. Culture guides targeted therapy and detects resistance.

"Short-Course Antibiotics are as Effective as Long-Course for Uncomplicated Cystitis": 3-day nitrofurantoin or trimethoprim achieves equivalent cure rates to 7-day courses with better compliance and less resistance development. Reserve longer durations for complicated infections. [9]

"Recurrent UTI ≥3 Episodes/Year May Benefit from Prophylaxis": Continuous low-dose prophylaxis (nitrofurantoin 50-100mg nocte) or post-coital prophylaxis reduces recurrence by 80-95%. Non-antibiotic options include topical vaginal estrogen (postmenopausal women), cranberry products (limited evidence), and behavioral modifications. [6,10]

Why This Matters Clinically

UTI represents a diagnostic and therapeutic challenge across multiple clinical contexts:

1. Diagnostic Precision: Distinguishing cystitis from pyelonephritis determines treatment setting (outpatient vs hospital), route (oral vs IV), and duration. Misclassifying pyelonephritis as simple cystitis risks progression to urosepsis, renal abscess, or bacteremia.

2. Antimicrobial Stewardship: UTI is the most common indication for antibiotic prescription in primary care and emergency departments. Inappropriate antibiotic selection, excessive duration, and treatment of asymptomatic bacteriuria contribute substantially to antimicrobial resistance. Evidence-based prescribing patterns directly impact community resistance rates.

3. Recurrence and Quality of Life: Recurrent UTI affects 20-30% of women and significantly impairs quality of life, sexual function, and psychological well-being. Effective prevention strategies—both pharmacological and non-pharmacological—can reduce symptom burden and healthcare utilization.

4. Special Populations: Pregnancy-associated UTI and asymptomatic bacteriuria require mandatory treatment to prevent preterm labor and low birthweight. Catheter-associated UTI (CAUTI) is the most common healthcare-associated infection, with implications for patient safety and hospital quality metrics.

5. Recognition of Urosepsis: UTI is a leading cause of sepsis and septic shock, particularly in elderly and immunocompromised patients. Early recognition of systemic inflammatory response syndrome (SIRS) criteria and prompt administration of IV antibiotics and fluid resuscitation are life-saving interventions.

---

2. Epidemiology

Prevalence and Incidence

Urinary tract infection demonstrates striking age- and gender-related patterns:

Geographical and Demographic Variations

Global Burden: UTI accounts for approximately 150 million cases annually worldwide, generating healthcare costs exceeding $3 billion in the United States alone. [1] Incidence is highest in developed countries with aging populations and extensive healthcare infrastructure (catheter use, instrumentation).

Gender Disparity Mechanisms:

• Anatomical: Shorter female urethra (4cm vs 20cm) facilitates bacterial ascent
• Hormonal: Estrogen loss in menopause alters vaginal pH and microbiome
• Sexual activity: "Honeymoon cystitis" from mechanical introduction of bacteria
• Pregnancy: Progesterone-induced ureteral dilation and vesicoureteral reflux

Age-Related Patterns:

• Infancy: Male > female (congenital abnormalities predominate)
• Childhood: Female > male (onset of anatomical risk)
• Reproductive years: Female >> male (sexual activity, pregnancy)
• Elderly: Gender gap narrows (male prostatic disease, female estrogen deficiency)

Risk Factors

Exam Detail: Host Factors:

Pathogen Factors:

E. coli strains causing UTI possess specific virulence factors:

• Type 1 fimbriae (pili): Mannose-sensitive adhesins binding bladder uroepithelium
• P fimbriae: Gal-Gal binding receptors facilitating renal ascent and pyelonephritis
• Hemolysin: Cytotoxin causing host cell lysis and inflammation
• Aerobactin: Siderophore enabling iron acquisition in iron-limited urinary environment
• Capsule (K antigen): Inhibits phagocytosis and complement-mediated killing [2]

Healthcare-Associated UTI

Catheter-associated urinary tract infection (CAUTI) is the most common healthcare-associated infection, accounting for 30-40% of hospital-acquired infections. [13]

Risk Progression:

• 3-10% daily risk of bacteriuria with indwelling catheter
• 100% bacteriuria by 30 days of catheterization
• 10-25% of bacteriuric catheterized patients develop symptomatic UTI
• Catheter biofilm formation protects bacteria from antibiotics and immunity

Prevention Strategies (reduce CAUTI by 50-70%):

• Avoid unnecessary catheterization (strongest evidence)
• Remove catheters as early as possible
• Aseptic insertion technique
• Closed drainage system maintenance
• Daily necessity review ("catheter bundle")

---

3. Aetiology and Pathophysiology

Microbiology of UTI

Community-Acquired UTI:

Healthcare-Associated/Catheter-Associated UTI:

• Greater organism diversity (E. coli 50%, Enterococcus 15%, Candida 10-15%, Pseudomonas 10%)
• Higher antimicrobial resistance rates (ESBL, carbapenemase-producing organisms)
• Polymicrobial infections more common (20-30% vs less than 5% community-acquired)

Pathophysiological Mechanisms

Exam Detail: #### Ascending Route of Infection

The ascending pathway accounts for > 95% of UTIs:

Step 1: Periurethral Colonization

• Fecal flora (E. coli, Enterococcus) colonize perineum and distal urethra
• Vaginal microbiome disruption (antibiotic use, estrogen deficiency) permits uropathogen overgrowth
• Sexual intercourse, catheterization mechanically introduce bacteria

Step 2: Urethral Ascent

• Bacteria traverse urethra via:
  • Active motility (flagella)
  • Passive mechanical forces (sexual activity, voiding turbulence)
  • Adherence to uroepithelium via fimbriae/pili
• Short female urethra (4cm) vs male urethra (20cm) explains gender disparity

Step 3: Bladder Colonization (Cystitis)

• Bacteria attach to bladder uroepithelium via type 1 fimbriae (FimH adhesin)
• Host defenses:
  • "Urine flow and voiding: Mechanical washout (most important)"
  • "Tamm-Horsfall protein: Binds bacteria, prevents epithelial adherence"
  • "Antimicrobial peptides: Defensins, cathelicidin in urine"
  • "Low pH: Inhibits many bacterial species"
  • "High urea, organic acids: Bacteriostatic environment"
• Bacterial invasion triggers inflammatory cascade:
  • TLR4 recognition of LPS → IL-8, IL-6 release
  • Neutrophil recruitment → pyuria
  • Uroepithelial damage → hematuria, dysuria

Step 4: Renal Ascent (Pyelonephritis)

• Occurs in 20-30% of untreated cystitis
• P fimbriae-expressing E. coli strains preferentially cause pyelonephritis
• Vesicoureteral reflux (VUR) facilitates bacterial ascent
• Pyelonephritis mechanisms:
  • Direct tubular invasion and damage
  • Renal parenchymal inflammation and abscess formation
  • Risk of bacteremia (20-30% of pyelonephritis) and sepsis
  • Potential for permanent renal scarring (especially with obstruction)

Hematogenous Route

Accounts for less than 3% of UTIs, typically in:

• Staphylococcus aureus bacteremia: Seeding of kidneys (renal abscess, perinephric abscess)
• Candida fungemia: ICU patients, immunocompromised
• Mycobacterium tuberculosis: Renal TB via hematogenous spread

Virulence Factors in Uropathogenic E. coli (UPEC)

Adhesins:

• Type 1 fimbriae: FimH tip adhesin binds mannosylated glycoproteins on bladder epithelium; mannose-sensitive hemagglutination
• P fimbriae (Pap pili): PapG adhesin binds Galα1-4Gal receptors on renal epithelium; associated with pyelonephritis and renal scarring [2]
• Dr adhesins: Bind decay-accelerating factor; pregnancy-associated pyelonephritis

Toxins:

• α-Hemolysin (HlyA): Forms pores in host cells; cytotoxic, promotes ascending infection
• Cytotoxic necrotizing factor 1 (CNF1): Modulates host cell signaling, enhances invasion

Iron Acquisition:

• Siderophores (aerobactin, enterobactin): Chelate iron from transferrin, lactoferrin; essential for bacterial growth in iron-poor urine

Immune Evasion:

• Capsule (K antigen): Prevents complement deposition and phagocytosis
• O antigen (LPS): Endotoxin; triggers systemic inflammatory response

Intracellular Bacterial Communities (IBCs):

• UPEC can invade bladder epithelial cells and form biofilm-like IBCs
• Provides sanctuary from antibiotics and immune clearance
• Reservoir for recurrent infection [14]

Host Defense Mechanisms

---

4. Clinical Presentation

Lower Urinary Tract Infection (Cystitis)

Classic Symptom Triad (sensitivity > 80% for UTI diagnosis in women with acute dysuria):

1. Dysuria: Burning or pain on micturition (90-95% of cystitis cases)
2. Urinary frequency: Voiding ≥8 times daily (80-90%)
3. Urinary urgency: Sudden compelling desire to void (75-85%)

Additional Features:

• Suprapubic or lower abdominal pain/discomfort (70%)
• Hematuria (macroscopic or microscopic; 30-40%)
• Cloudy or malodorous urine (60%)
• Nocturia (50%)
• Absence of fever, chills, or systemic symptoms (key distinguishing feature from pyelonephritis)

Clinical Diagnosis Probability (in women presenting with acute dysuria):

• Dysuria + frequency without vaginal discharge/irritation: 90% probability of UTI [15]
• Addition of hematuria or costovertebral angle tenderness: 95% probability
• Presence of vaginal discharge or irritation: less than 25% probability (suggests vaginitis/STI)

Upper Urinary Tract Infection (Pyelonephritis)

Clinical Features:

• Fever: ≥38°C (90-95% of cases); often high-grade with rigors
• Loin/flank pain: Unilateral or bilateral (85-90%)
• Costovertebral angle (CVA) tenderness: Percussion tenderness over kidneys (75-85%)
• Nausea and vomiting: (60-70%)
• Lower urinary tract symptoms: May coexist but often less prominent

Severity Markers (suggest need for hospitalization):

• Temperature > 39°C or less than 36°C
• Persistent vomiting (unable to tolerate oral antibiotics/fluids)
• Hemodynamic instability (tachycardia > 100 bpm, systolic BP less than 90 mmHg)
• Altered mental status (especially elderly)
• Signs of sepsis (SIRS criteria: temperature, heart rate, respiratory rate, WBC abnormalities)
• Acute kidney injury (rising creatinine, oliguria)

Complicated UTI Presentations

Catheter-Associated UTI (CAUTI):

• Asymptomatic bacteriuria is universal with long-term catheterization (do not treat)
• Symptomatic CAUTI: New onset fever (> 38°C), suprapubic pain, costovertebral tenderness, altered mental status, or sepsis in absence of other sources
• Cloudy urine or malodor alone does not indicate symptomatic infection

UTI in Men:

• Always "complicated" by definition
• Consider prostatitis if: perineal/rectal pain, obstructive symptoms, tender prostate on DRE
• Investigate for structural abnormality (BPH, stones, stricture) especially if first episode

UTI in Pregnancy:

• Asymptomatic bacteriuria (ASB): 2-7% prevalence; screen all pregnant women at 12-16 weeks
• Symptomatic cystitis: As per non-pregnant women
• Pyelonephritis: More severe in pregnancy; risk of preterm labor, maternal sepsis, fetal compromise [7]

UTI in Elderly/Institutionalized:

• Atypical presentations common: confusion, falls, functional decline, hypothermia
• Asymptomatic bacteriuria prevalence: 20-50% (women), 5-20% (men)—do not treat
• Nonspecific symptoms (confusion alone) should not prompt empirical UTI treatment without supporting evidence [8]

Recurrent UTI:

• Defined as ≥3 episodes in 12 months OR ≥2 episodes in 6 months
• Relapse: Same organism less than 2 weeks after treatment (suggests focus: renal calculus, abscess)
• Reinfection: Different organism or > 2 weeks interval (most common pattern; 80% of recurrent UTI)

Red Flags and Differential Diagnoses

Clinical Pearl: Red Flags Requiring Urgent Assessment:

• Sepsis criteria (fever + tachycardia + hypotension ± altered mental status)
• Obstructive uropathy symptoms (anuria, severe loin pain, palpable bladder)
• Pregnancy with any UTI symptoms
• Immunocompromised host with UTI
• Recent urological instrumentation/surgery
• Persistent symptoms despite 48-72 hours of appropriate antibiotics
• Acute kidney injury (rising creatinine, oliguria)

Differential Diagnoses in Dysuria:

---

5. Clinical Examination

General Examination

Vital Signs Assessment (essential for all suspected UTI):

• Temperature: Fever ≥38°C suggests upper UTI or complicated infection; hypothermia (less than 36°C) may indicate sepsis in elderly
• Heart rate: Tachycardia (> 100 bpm) suggests systemic response; marker of severity
• Blood pressure: Hypotension (systolic less than 90 mmHg) indicates possible urosepsis
• Respiratory rate: Tachypnea (> 20/min) suggests sepsis or metabolic acidosis

General Appearance:

• Level of consciousness and orientation (confusion suggests sepsis or elderly UTI presentation)
• Signs of distress or toxicity
• Hydration status (dry mucous membranes, reduced skin turgor)

Abdominal Examination

Inspection:

• Distended bladder (suprapubic fullness in urinary retention)
• Surgical scars (previous urological surgery)

Palpation:

• Suprapubic tenderness: Common in cystitis (70-80%)
• Palpable bladder: Acute or chronic retention (obstruction, neurogenic bladder)
• Renal masses: Enlargement (hydronephrosis), tenderness (pyelonephritis, abscess)

Percussion:

• Costovertebral angle (CVA) tenderness: Fist percussion over renal angles posteriorly
  • Positive in 75-85% of pyelonephritis (Murphy's punch sign)
  • Unilateral tenderness suggests ipsilateral kidney involvement

Auscultation:

• Rarely contributory in UTI assessment

Genitourinary Examination

Female Patients:

• External inspection: Vulvovaginal erythema, discharge (suggests vaginitis rather than UTI)
• Speculum examination (if vaginal symptoms present): Cervicitis, discharge
• Bimanual examination (if pelvic pain): Cervical motion tenderness, adnexal tenderness (PID)

Male Patients:

• External genitalia: Urethral discharge (urethritis), testicular tenderness (epididymo-orchitis)
• Digital rectal examination (DRE): Mandatory in men with UTI
  • Prostatic enlargement (BPH)
  • Prostatic tenderness/bogginess (acute prostatitis—contraindication to vigorous massage)
  • Prostatic nodules (cancer)

Catheter Assessment (if present)

• Catheter type and duration in situ
• Position and patency (blockage common with Proteus infection and encrustation)
• Urine appearance in drainage bag (hematuria, pyuria, debris)
• Suprapubic or urethral route

Systems Examination (if sepsis suspected)

• Cardiovascular: Capillary refill, peripheral perfusion
• Respiratory: Tachypnea, reduced air entry (secondary to sepsis)
• Neurological: GCS, focal deficits (elderly with confusion)

---

6. Investigations

Urine Dipstick Testing

Interpretation in Suspected Cystitis:

Key Points:

• Nitrites: Produced by Gram-negative bacteria (E. coli, Klebsiella, Proteus) from dietary nitrates; false negatives occur if urine dwelling time less than 4 hours, low dietary nitrate, or non-nitrite-producing organisms (Enterococcus, Staph)
• Leukocyte esterase: Detects WBC presence; false positives with vaginal contamination, sterile pyuria (TB, interstitial nephritis)
• Negative dipstick: Reduces UTI probability to less than 20% in low-risk patients [16]
• Do not use dipstick in catheterized patients (high false-positive rate; asymptomatic bacteriuria universal)

Urine Microscopy and Culture

Midstream Urine (MSU) Collection:

• Clean-catch technique after external cleansing
• Midstream portion (discard first 20-30ml to reduce contamination)
• Process within 4 hours or refrigerate at 4°C

Microscopy Findings:

• Pyuria: > 10 WBC/mm³ (or > 10 WBC/high-power field)
  • Present in 90-95% of UTI but non-specific
  • "Sterile pyuria: Tuberculosis, interstitial nephritis, urolithiasis, partially treated UTI"
• Bacteriuria: Visible bacteria on Gram stain
• Hematuria: RBCs present
• Casts: WBC casts suggest pyelonephritis (upper tract inflammation)

Culture Interpretation:

• ≥10⁵ CFU/ml: Traditional threshold for UTI diagnosis (95% specificity)
• ≥10³ CFU/ml: Significant in symptomatic women with pyuria (90% sensitivity, 90% specificity) [17]
• ≥10² CFU/ml: May be significant in catheterized patients or suprapubic aspirates
• Mixed growth (≥3 organisms): Usually contamination; repeat sample
• No growth despite symptoms: Consider partially treated UTI, fastidious organisms, urethritis, interstitial cystitis

Antimicrobial Susceptibility Testing:

• Performed on all positive cultures
• Guides therapy in treatment failure, recurrent UTI, pyelonephritis, complicated infections
• Reports resistance patterns for antimicrobial stewardship

Indications for Urine Culture (Before Starting Antibiotics)

Mandatory:

• Men with UTI (all cases)
• Pregnant women
• Suspected pyelonephritis
• Catheter-associated UTI
• Healthcare-associated UTI
• Recurrent UTI
• Treatment failure (persistent symptoms at 48-72 hours)
• Immunocompromised patients
• Children
• Recent urological instrumentation

Not routinely required:

• Uncomplicated cystitis in non-pregnant women (empirical treatment appropriate if typical symptoms)

Blood Tests

Full Blood Count (FBC):

• Leukocytosis (WBC > 11×10⁹/L): Suggests systemic infection (pyelonephritis, sepsis)
• Neutrophilia: Bacterial infection
• Left shift: Immature neutrophils; severe infection

Renal Function (U&E, Creatinine):

• Baseline assessment in pyelonephritis
• Detect acute kidney injury: Obstruction, severe pyelonephritis, sepsis-induced AKI
• Guide antibiotic dosing (many renally excreted)

Inflammatory Markers:

• CRP: Elevated in pyelonephritis (typically 50-200 mg/L)
• Procalcitonin: May help differentiate bacterial infection from non-infectious inflammation (limited UTI-specific evidence)

Blood Cultures:

• Indicated if:
  • Suspected sepsis or severe pyelonephritis
  • Immunocompromised host
  • Hospital-acquired UTI
  • Persistent fever despite antibiotics
• Positive in 20-30% of pyelonephritis cases (bacteremia)

Imaging

Indications for Renal Tract Imaging:

Ultrasound Renal Tract:

• First-line in pregnancy, children, assessing hydronephrosis
• Detects: Kidney size, hydronephrosis, large stones (> 5mm), renal/perinephric abscess
• Limitations: Misses small stones, ureteric pathology, emphysematous changes

CT KUB (non-contrast):

• Gold standard for urolithiasis (sensitivity > 95%)
• Detects all stone types (including radiolucent uric acid stones)

CT with IV contrast (CT urogram):

• Best modality for complex/recurrent pyelonephritis
• Identifies: Abscess, emphysematous pyelonephritis, anatomical abnormalities, transitional cell carcinoma
• Contraindications: Renal impairment (eGFR less than 30), contrast allergy

---

7. Classification and Definitions

Clinical Classification

Uncomplicated vs Complicated UTI:

Anatomical Classification:

• Lower UTI: Infection confined to bladder (cystitis) or urethra (urethritis)
• Upper UTI: Infection involving renal parenchyma (pyelonephritis), renal pelvis (pyelitis), or perinephric tissues (perinephric abscess)

Recurrent UTI Definitions

Recurrent UTI (rUTI):

• ≥3 symptomatic episodes in 12 months, OR
• ≥2 symptomatic episodes in 6 months

Patterns:

• Relapse (20%): Same organism within 2 weeks of completing treatment
  • Suggests persistent focus (renal calculus, abscess, prostatic focus)
  • Requires imaging and prolonged antibiotics (4-6 weeks)
• Reinfection (80%): Different organism, or same organism > 2 weeks after treatment
  • Most common pattern
  • Managed with behavioral modifications ± prophylaxis

Special UTI Syndromes

Asymptomatic Bacteriuria (ASB):

• Significant bacteriuria (≥10⁵ CFU/ml) in absence of UTI symptoms
• Prevalence: 2-10% young women, 20-50% elderly institutionalized women, 100% long-term catheterized patients
• Treatment indicated ONLY in:
  • Pregnancy (all trimesters)
  • Before urological instrumentation/surgery
• Do NOT treat in: Elderly, catheterized, diabetic, or pre-renal transplant patients (no benefit; drives resistance) [8]

Catheter-Associated UTI (CAUTI):

• Symptomatic UTI in patient with indwelling urethral, suprapubic, or intermittent catheter, OR removed within 48 hours
• Symptoms required: Fever > 38°C, new costovertebral tenderness, acute hematuria, pelvic discomfort, OR in those whose catheter is removed: dysuria, urgency, frequency, suprapubic pain
• Cloudy urine or malodor alone does NOT constitute symptomatic CAUTI

Emphysematous Pyelonephritis:

• Severe necrotizing infection with gas formation in renal parenchyma/perinephric tissues
• Almost exclusively in diabetics (90% of cases)
• Organisms: E. coli (70%), Klebsiella (20%)
• High mortality (20-40%); requires IV antibiotics ± nephrectomy

Xanthogranulomatous Pyelonephritis:

• Chronic destructive infection with granulomatous inflammation
• Associated with obstruction (staghorn calculi) and Proteus mirabilis
• Requires nephrectomy

Renal/Perinephric Abscess:

• Focal collection of pus within renal parenchyma or perinephric space
• Sources: Ascending UTI (60%), hematogenous seeding from S. aureus bacteremia (30%)
• Requires prolonged antibiotics (4-6 weeks) ± percutaneous/surgical drainage

---

8. Management

General Principles

Antimicrobial Stewardship Priorities:

1. Empirical therapy: Choose based on local resistance patterns and severity
2. Narrow spectrum preferred: Avoid broad-spectrum agents (fluoroquinolones, cephalosporins) for uncomplicated infections
3. Shortest effective duration: 3 days for uncomplicated cystitis; 7-14 days for pyelonephritis
4. De-escalate based on culture: Switch from IV to oral; narrow spectrum once sensitivities known
5. Avoid treating asymptomatic bacteriuria: Except pregnancy and pre-urological procedures [8]

Uncomplicated Cystitis (Non-Pregnant Women)

First-Line Antibiotics (choose based on local resistance less than 20%): [3]

Second-Line (if resistance or contraindications):

• Nitrofurantoin MR: 100mg BD for 5-7 days (if eGFR ≥45)
• Cefalexin: 500mg BD for 3 days (cephalosporin; broader spectrum)

NOT Recommended for Routine Use (reserve for resistant organisms):

• Ciprofloxacin: Drives resistance; adverse effects (C. difficile, Achilles tendon rupture); use only if no alternatives
• Co-amoxiclav: Broader spectrum; higher adverse effect rate

Symptomatic Relief:

• Analgesia: Paracetamol 1g QDS, ibuprofen 400mg TDS (NSAIDs reduce dysuria)
• Fluids: Encourage oral hydration (2-3L/day); no evidence for "flushing" bacteria but maintains urine flow
• Urinary alkalinizers (potassium citrate): Limited evidence; may provide symptomatic relief

Expected Response:

• Symptoms improve within 24-48 hours in 90% of cases
• If no improvement at 48 hours: Send urine culture (if not done), review antibiotic choice, consider complicated UTI

Follow-Up:

• Not required if symptoms resolve
• Urine culture post-treatment unnecessary in asymptomatic patients
• Advise to return if symptoms persist > 48-72 hours or recur within 2 weeks

Uncomplicated Pyelonephritis

Assessment of Severity:

Antibiotic Therapy:

Outpatient (Mild Pyelonephritis):

Inpatient (Moderate-Severe Pyelonephritis):

Initial IV therapy (until afebrile for 24-48 hours, then switch to oral):

• Ceftriaxone: 1-2g IV daily, OR
• Co-amoxiclav: 1.2g IV TDS, OR
• Gentamicin: 5-7mg/kg IV daily (renal function monitoring required), OR
• Ciprofloxacin: 400mg IV BD (if oral not tolerated)

Oral switch (step-down after clinical improvement):

• Continue same antibiotic class orally to complete 10-14 days total
• De-escalate based on culture sensitivities

Supportive Care:

• IV fluids if vomiting/dehydrated
• Analgesia (paracetamol ± opioids for severe pain)
• Antiemetics (ondansetron, metoclopramide)

Monitoring:

• Daily observations (temperature, HR, BP)
• Repeat bloods at 48-72h if not improving (FBC, CRP, creatinine)
• Imaging (CT) if fever persists > 72 hours despite antibiotics (? abscess, obstruction)

Complicated UTI

Principles:

• Longer duration: 7-14 days minimum (up to 4-6 weeks for renal abscess, prostatic focus)
• Always send urine culture before antibiotics
• Broader spectrum empirical therapy
• IV antibiotics for severe cases or if oral not tolerated
• Identify and address underlying cause (obstruction, stones, catheter, prostate)

Empirical Therapy:

• Similar to pyelonephritis (ceftriaxone, co-amoxiclav, gentamicin)
• De-escalate based on culture

Specific Contexts:

Pregnancy and UTI

Asymptomatic Bacteriuria:

• Screen all pregnant women at 12-16 weeks with MSU culture [7]
• Treat if ≥10⁵ CFU/ml (even if asymptomatic)
• Antibiotics: Cefalexin 500mg BD or TDS for 7 days, OR Nitrofurantoin 100mg MR BD for 7 days (avoid in 3rd trimester due to neonatal hemolysis risk)
• Repeat urine culture 1 week post-treatment and monthly thereafter

Symptomatic Cystitis:

• As per ASB treatment (cefalexin or nitrofurantoin for 7 days)

Pyelonephritis:

• Always admit due to high risk of preterm labor and maternal/fetal compromise
• IV antibiotics: Ceftriaxone 1-2g IV daily OR co-amoxiclav 1.2g IV TDS
• Switch to oral when afebrile (cefalexin, amoxicillin based on sensitivities)
• Total duration: 10-14 days
• Fetal monitoring (CTG if viable gestation)
• Consider tocolysis if preterm contractions

Antibiotics to AVOID in Pregnancy:

• Trimethoprim: Folate antagonist; teratogenic in 1st trimester
• Fluoroquinolones: Arthropathy risk (cartilage damage)
• Nitrofurantoin > 36 weeks: Neonatal hemolysis

Recurrent UTI

Diagnostic Approach:

• Urine culture during symptomatic episode (confirm diagnosis, exclude resistance)
• Relapse pattern (same organism less than 2 weeks): Investigate for focus
  • Renal ultrasound ± CT urogram (stones, anatomical abnormality)
  • "Men: DRE, consider prostate imaging if recurrent (chronic prostatitis)"
  • Treat underlying cause + prolonged antibiotics (4-6 weeks)
• Reinfection pattern (different organism or > 2 weeks): Behavioral ± prophylaxis

Non-Antimicrobial Prevention Strategies:

Antimicrobial Prophylaxis:

Indicated if ≥3 UTIs in 12 months OR ≥2 in 6 months, AND non-antimicrobial measures insufficient.

Continuous Prophylaxis:

Post-Coital Prophylaxis (if UTIs clearly intercourse-related):

• Same antibiotics, single dose within 2 hours of intercourse
• Equally effective as continuous prophylaxis with less antibiotic exposure

Duration:

• Initial trial 6-12 months
• Discontinue and monitor; restart if recurrence
• Balance efficacy against antimicrobial resistance concerns

Methenamine Hippurate:

• Non-antibiotic urinary antiseptic
• 1g BD long-term
• Converts to formaldehyde in acidic urine (bactericidal)
• Modest efficacy; used when antibiotics contraindicated/not tolerated

Catheter-Associated UTI (CAUTI)

Prevention (most important):

• Avoid unnecessary catheterization
• Remove catheters as soon as possible (daily review)
• Aseptic insertion technique
• Closed drainage system maintenance
• Avoid routine catheter changes unless blocked/damaged

Treatment of Symptomatic CAUTI:

• Remove or change catheter before starting antibiotics (biofilm source)
• Empirical antibiotics as per complicated UTI (broader spectrum): Ceftriaxone, co-amoxiclav, gentamicin
• Duration: 7 days (same as uncomplicated pyelonephritis)
• De-escalate based on culture

Do NOT Treat:

• Asymptomatic bacteriuria (universal in long-term catheters; no benefit from treatment)
• Cloudy/malodorous urine alone without systemic symptoms

---

9. Complications and Prognosis

Acute Complications

Chronic/Long-Term Complications

Recurrent UTI:

• 25-30% of women experience recurrence within 6 months [6]
• 44-50% recurrence within 12 months
• Quality of life impact: Anxiety, sexual dysfunction, healthcare costs
• Management: Behavioral modifications, vaginal estrogen (postmenopausal), prophylactic antibiotics

Renal Scarring:

• Occurs in 10-20% of pyelonephritis cases
• Higher risk: Children, VUR, recurrent pyelonephritis, delayed treatment
• Long-term risk of hypertension, chronic kidney disease
• Prevention: Early diagnosis and treatment

Antimicrobial Resistance:

• Patient-level: Repeated antibiotic exposure selects resistant strains (ESBL, fluoroquinolone resistance)
• Population-level: Excessive UTI antibiotic use contributes to community resistance patterns [4]
• Mitigation: Shortest effective duration, narrow-spectrum agents, avoid treating ASB

Chronic Kidney Disease:

• Rare complication of severe/recurrent pyelonephritis with scarring
• More common if underlying anatomical abnormality (VUR, obstruction)

Prognosis

Uncomplicated Cystitis:

• 90% clinical cure with appropriate antibiotics
• Symptoms improve within 24-48 hours
• Bacteriological cure (negative culture post-treatment): 85-95%
• Recurrence: 25-30% within 6 months

Pyelonephritis:

• Clinical improvement expected within 48-72 hours of antibiotics
• Fever typically resolves by day 3-4
• 5-10% require admission for IV therapy
• Mortality rare (less than 1%) in healthy adults; higher in elderly/immunocompromised (5-10%)
• Progression to CKD rare unless recurrent or underlying renal disease

Urosepsis:

• Mortality 10-20% overall
• Higher in elderly (20-30%), immunocompromised, delayed treatment
• Good prognosis if early recognition and appropriate antibiotics

Pregnancy:

• Untreated ASB → 20-40% develop pyelonephritis [7]
• Pyelonephritis → 10-20% preterm delivery risk
• With treatment: Excellent maternal and fetal outcomes

---

10. Prevention and Screening

Primary Prevention

General Population (Women):

• Increase fluid intake (1.5-2L/day) [19]
• Post-coital voiding
• Void regularly (avoid prolonged holding)
• Wipe front-to-back after defecation
• Avoid spermicides (if recurrent UTI) [11]
• Avoid douching, vaginal deodorants (disrupt microbiome)

Postmenopausal Women:

• Vaginal estrogen cream (estriol 0.5mg intravaginally twice weekly): Reduces recurrent UTI by 50% [10]
• Alternative to continuous antibiotics

Behavioral Modifications (Limited Evidence):

• Cranberry products (juice, tablets): Meta-analyses show small/inconsistent effect [20]
• Cotton underwear vs synthetic: No proven benefit
• Type of contraception: Diaphragm + spermicide associated with increased risk

Secondary Prevention (Preventing Recurrence)

Risk Stratification:

• ≥3 UTIs in 12 months OR ≥2 in 6 months = recurrent UTI requiring prevention strategies
• Identify relapse vs reinfection pattern (guides investigation)

Non-Antimicrobial Strategies (first-line):

• As per primary prevention
• Vaginal estrogen if postmenopausal [10]
• Increased fluid intake (specific RCT evidence: 1.5L extra water/day reduces UTI by 50%) [19]

Antimicrobial Prophylaxis (if non-antimicrobial strategies fail):

• Continuous: Nitrofurantoin 50-100mg nocte for 6-12 months
• Post-coital: Single dose after intercourse (if intercourse-related)
• Efficacy: Reduces recurrence by 80-95% [6]
• Risk: Antimicrobial resistance, adverse effects, cost

Investigate and Treat Underlying Causes:

• Postmenopausal atrophy → vaginal estrogen
• Incomplete bladder emptying → pelvic floor physiotherapy, timed voiding
• Stones → removal (ESWL, ureteroscopy)
• Prostatic disease → alpha-blockers, 5-alpha-reductase inhibitors, TURP

Screening

Pregnancy:

• Universal screening for asymptomatic bacteriuria at 12-16 weeks gestation (MSU culture) [7]
• Rationale: Prevents progression to pyelonephritis (20-40% if untreated), preterm labor, low birthweight
• Rescreen monthly if positive, post-treatment

Pre-Urological Procedures:

• Screen and treat ASB before:
  • TURP, ureteroscopy, PCNL
  • Cystoscopy with biopsy/resection
  • Any procedure breaching urinary tract mucosa
• Rationale: Prevents post-procedure sepsis

Do NOT Screen:

• Elderly, institutionalized (ASB prevalence 20-50%; treatment does not reduce symptomatic UTI) [8]
• Diabetic patients (ASB treatment no benefit)
• Catheterized patients (universal ASB; treatment drives resistance)
• Pre-renal transplant (previously recommended; now evidence shows no benefit)

Healthcare-Associated Infection Prevention (CAUTI)

Evidence-Based "Catheter Bundle":

1. Avoid unnecessary catheterization (strongest intervention)
2. Aseptic insertion technique
3. Maintain closed drainage system
4. Secure catheter (prevent urethral trauma)
5. Daily review of necessity and remove as soon as possible
6. Do not routinely change catheters unless blocked/damaged

Impact: Bundle implementation reduces CAUTI by 50-70% [13]

---

11. Evidence and Guidelines

Key Guidelines

1. National Institute for Health and Care Excellence (NICE)

• NG109: Urinary tract infection (lower): antimicrobial prescribing (2018)

  • "First-line: Nitrofurantoin, trimethoprim (if resistance less than 20%)"
  • "Duration: 3 days for uncomplicated cystitis"
  • Avoid routine use of quinolones for uncomplicated UTI
  • "Available: https://www.nice.org.uk/guidance/ng109"

• NG111: Pyelonephritis (acute): antimicrobial prescribing (2018)

  • "Outpatient: Ciprofloxacin 7 days (first-line)"
  • "Inpatient: IV ceftriaxone or co-amoxiclav"
  • "Available: https://www.nice.org.uk/guidance/ng111"

2. European Association of Urology (EAU)

• Guidelines on Urological Infections (2023)
  • Comprehensive guidance on complicated UTI, catheter-associated UTI, recurrent UTI
  • Antimicrobial resistance considerations
  • "Available: https://uroweb.org/guidelines/urological-infections"

3. Infectious Diseases Society of America (IDSA)

• Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria (2019)
  • Do not treat ASB except in pregnancy and pre-urological procedures [8]
  • Evidence synthesis on lack of benefit in elderly, diabetic, catheterized patients

4. American College of Obstetricians and Gynecologists (ACOG)

• Practice Bulletin: Urinary Tract Infections in Pregnancy (2008, reaffirmed 2016)
  • Screen all pregnant women for ASB at 12-16 weeks
  • Treat ASB to prevent pyelonephritis and preterm birth [7]

Landmark Evidence

Uncomplicated Cystitis Treatment Duration:

• Cochrane Review (Milo et al., 2005): 3-day vs 5-7 day antibiotic courses for uncomplicated UTI
  • "Outcome: Equivalent efficacy; shorter courses improve compliance [9]"
  • "Impact: Guideline adoption of 3-day regimens as standard"

Asymptomatic Bacteriuria Treatment:

• Cochrane Review (Zalmanovici Trestioreanu et al., 2015): Treatment of ASB in non-pregnant adults
  • "Outcome: No reduction in symptomatic UTI or mortality in elderly/institutionalized [8]"
  • "Impact: Strong recommendation AGAINST treating ASB outside pregnancy/pre-procedure"

Recurrent UTI Prevention:

• Antibiotic Prophylaxis RCTs: Continuous low-dose antibiotics reduce recurrence by 80-95% [6]
• Vaginal Estrogen RCT (Raz & Stamm, 1993): Topical estriol reduces rUTI by 50% in postmenopausal women [10]
• Increased Water Intake RCT (Hooton et al., 2018): Additional 1.5L water/day reduces UTI by 48% [19]

Cranberry Products:

• Cochrane Review (Jepson et al., 2012): Cranberry products for preventing UTI
  • "Outcome: Small reduction in recurrent UTI; high dropout rates; benefit uncertain [20]"
  • "Impact: Weak recommendation; not first-line"

Catheter-Associated UTI Prevention:

• Silver-Alloy Catheters Meta-Analysis: No significant reduction in CAUTI vs standard catheters
• Antimicrobial-Coated Catheters: Limited/no benefit
• Catheter Removal RCTs: Early removal reduces CAUTI by 50-70% [13]

Current Controversies and Evolving Evidence

1. Urine Culture Thresholds:

• Traditional ≥10⁵ CFU/ml threshold questioned
• Evidence supports ≥10³ CFU/ml in symptomatic women with pyuria [17]
• Debate ongoing regarding "low-count bacteriuria"

2. Fosfomycin for Pyelonephritis:

• Single 3g dose highly effective for cystitis
• Emerging evidence for multi-dose regimens in pyelonephritis
• Potential alternative in multidrug-resistant organisms

3. Microbiome-Based Interventions:

• Lactobacillus probiotics: Conflicting evidence; strain-specific effects likely
• Fecal microbiota transplant (FMT): Experimental for recurrent UTI due to gut-bladder axis

4. Non-Antibiotic Prophylaxis:

• D-Mannose: Small RCTs show promise; larger trials needed
• Methenamine hippurate: Meta-analyses show modest benefit; underutilized
• Immunostimulants (OM-89): Used in Europe; limited US/UK uptake

5. Antimicrobial Resistance:

• ESBL-producing E. coli: Increasing globally (10-15% community, 20-30% healthcare)
• Fluoroquinolone resistance: 15-30% in many regions [4]
• Carbapenem-resistant Enterobacteriaceae (CRE): Emerging threat
• Impact: Narrowing empirical options; need for rapid diagnostics and novel agents

---

12. Examination Focus

Viva Voce Questions and Model Answers

Exam Detail: Question 1: "A 28-year-old woman presents with 48 hours of dysuria and frequency. How would you assess and manage her?"

Model Answer: "This presentation is consistent with uncomplicated cystitis. I would take a focused history to confirm typical symptoms—dysuria, frequency, urgency, suprapubic pain—and exclude upper UTI features (fever, loin pain) or vaginal symptoms (discharge, irritation) which would suggest alternative diagnoses like pyelonephritis or STI.

On examination, I'd check vital signs (fever suggests upper UTI), palpate for suprapubic tenderness, and assess for CVA tenderness. In a healthy, non-pregnant woman with typical cystitis symptoms and no vaginal symptoms, clinical diagnosis is sufficient, and empirical treatment without urine culture is appropriate per NICE guidance.

First-line antibiotics are nitrofurantoin 100mg modified-release twice daily for 3 days or trimethoprim 200mg twice daily for 3 days if local resistance is below 20%. I'd advise symptomatic relief with fluids and simple analgesia, and safety-net to return if symptoms persist beyond 48-72 hours, worsen, or she develops fever or loin pain—at which point I'd send urine culture and consider pyelonephritis.

This short-course approach balances efficacy with antimicrobial stewardship, as 3-day regimens achieve equivalent cure rates to longer courses with better compliance and less resistance."

---

Question 2: "A 55-year-old diabetic man presents with his first UTI. What are your concerns and investigative approach?"

Model Answer: "UTI in men is complicated by definition due to anatomical protection from the longer urethra, so a first episode warrants investigation for underlying structural or functional abnormality. Combined with diabetes, this patient has increased infection susceptibility.

My concerns include:

1. Prostatic disease: BPH, chronic prostatitis, or malignancy causing incomplete emptying
2. Urolithiasis: Stones predisposing to stasis and infection
3. Urethral stricture: From previous instrumentation or STI
4. Neurogenic bladder: Diabetic autonomic neuropathy causing high post-void residual

I would perform digital rectal examination to assess prostate size, consistency, and tenderness. I'd send midstream urine for culture before starting antibiotics to guide targeted therapy and detect resistance, which is more common in diabetics.

Initial investigations include renal function (diabetes baseline), urine culture, and renal tract ultrasound to assess for hydronephrosis, stones, post-void residual, and prostatic enlargement. If recurrent UTI or atypical features, I'd consider CT urogram or cystoscopy.

Antibiotic choice should cover typical uropathogens with good prostatic penetration if prostatitis suspected—fluoroquinolones like ciprofloxacin or trimethoprim for 7-14 days rather than the 3-day course used in uncomplicated cystitis. I'd treat the underlying cause if identified—alpha-blockers for BPH, stone removal, or glycemic optimization."

---

Question 3: "Explain the pathophysiology of ascending UTI from E. coli colonization to pyelonephritis."

Model Answer: "E. coli ascending infection follows four stages:

Stage 1: Periurethral Colonization Fecal E. coli colonize the perineum and distal urethra. Risk factors include vaginal microbiome disruption from antibiotic use, estrogen deficiency post-menopause altering pH and lactobacilli dominance, or spermicide use which promotes E. coli overgrowth.

Stage 2: Urethral Ascent and Bladder Invasion Bacteria traverse the urethra via active flagellar motility and mechanical forces like sexual intercourse. The short female urethra—4cm versus 20cm in males—explains the gender disparity. Upon reaching the bladder, uropathogenic E. coli express type 1 fimbriae with FimH adhesins that bind mannosylated uroplakin receptors on bladder uroepithelium, enabling attachment despite high urine flow.

Stage 3: Bladder Colonization (Cystitis) Attached bacteria multiply and invade superficial uroepithelial cells, forming intracellular bacterial communities (IBCs) that evade immune clearance and antibiotics. Bacterial lipopolysaccharide triggers TLR4-mediated innate immunity, releasing IL-6 and IL-8, recruiting neutrophils—manifest as pyuria. Uroepithelial damage causes hematuria and dysuria. Host defenses include mechanical voiding, Tamm-Horsfall protein (binds bacteria), low pH, and antimicrobial peptides, but virulent strains overcome these.

Stage 4: Renal Ascent (Pyelonephritis) A subset of E. coli strains expressing P fimbriae—which bind Galα1-4Gal receptors on renal tubular epithelium—preferentially ascend to the kidneys, aided by vesicoureteral reflux if present. Renal parenchymal invasion triggers intense inflammation with risk of abscess formation, bacteremia in 20-30%, and potential permanent scarring if obstruction coexists.

Additional virulence factors include hemolysin (cytotoxic), aerobactin (iron acquisition in iron-poor urine), and capsule (immune evasion). This stepwise pathophysiology explains why only 20-30% of untreated cystitis progress to pyelonephritis, and why targeting virulence factors is an area of therapeutic research."

---

Question 4: "A pregnant woman at 14 weeks gestation has asymptomatic bacteriuria on routine screening. Justify treatment."

Model Answer: "Pregnancy is one of only two indications—alongside pre-urological instrumentation—where asymptomatic bacteriuria must be treated. The rationale is compelling:

Epidemiology: ASB prevalence in pregnancy is 2-7%. If untreated, 20-40% progress to pyelonephritis, compared to less than 1% if treated. Pregnancy-related physiological changes predispose to this:

• Progesterone causes ureteral smooth muscle relaxation and dilation
• Mechanical compression from gravid uterus causes urinary stasis
• Relative immunosuppression
• Glycosuria in 10-15% promotes bacterial growth

Maternal Consequences: Pyelonephritis in pregnancy is severe, with risks of:

• Sepsis and septic shock
• Acute kidney injury
• Anemia (hemolysis from bacterial toxins)
• ARDS in severe cases

Fetal Consequences:

• Preterm labor (10-20% of pyelonephritis cases)
• Low birthweight
• Fetal compromise from maternal sepsis

Treatment: I would treat with pregnancy-safe antibiotics achieving high urinary concentrations: cefalexin 500mg BD-TDS for 7 days (first-line) or nitrofurantoin 100mg MR BD for 7 days (avoid in third trimester due to neonatal hemolysis risk). Trimethoprim is avoided in first trimester as a folate antagonist (teratogenic risk).

Follow-Up: Repeat urine culture one week post-treatment to confirm eradication, then monthly screening for remainder of pregnancy, as 20-30% experience recurrence.

This is high-quality evidence from RCTs and Cochrane reviews showing that treating ASB in pregnancy reduces pyelonephritis by 75% and preterm delivery, whereas treating ASB in non-pregnant populations (elderly, diabetic, catheterized) shows no benefit and drives resistance—hence the selective approach."

---

Question 5: "Discuss antimicrobial stewardship principles in UTI management."

Model Answer: "UTI is the most common indication for antibiotics in primary care and emergency departments, making it a critical target for antimicrobial stewardship. Poor prescribing drives resistance and patient harm.

Principle 1: Diagnostic Precision Distinguish true UTI from asymptomatic bacteriuria, contamination, or alternative diagnoses. Treating ASB in non-pregnant adults is the most common error—it provides no benefit in elderly, diabetic, or catheterized patients but selects resistant organisms. Dipstick testing in catheterized patients yields false positives universally and should be avoided.

Principle 2: Appropriate Empirical Therapy Choose narrow-spectrum agents effective against likely pathogens with minimal collateral damage:

• First-line for cystitis: Nitrofurantoin or trimethoprim (if local resistance less than 20%)
• Avoid routine fluoroquinolones: Broad spectrum, drives resistance, C. difficile risk, Achilles rupture
• Avoid co-amoxiclav: Unless specific indication; higher adverse effects
• Reserve broad-spectrum (ceftriaxone, carbapenems) for severe sepsis or known ESBL organisms

Principle 3: Shortest Effective Duration Evidence shows 3-day courses for uncomplicated cystitis achieve equivalent cure rates to 7 days with better compliance and less resistance. Longer durations (7-14 days) are reserved for pyelonephritis and complicated UTI.

Principle 4: De-Escalation Based on Culture Send urine culture before antibiotics in complicated UTI, men, pregnancy, recurrent UTI, or treatment failure. Switch from empirical broad-spectrum to targeted narrow-spectrum based on sensitivities—e.g., IV ceftriaxone to oral trimethoprim if E. coli susceptible.

Principle 5: Non-Antibiotic Alternatives For recurrent UTI, prioritize non-antimicrobial prevention: increased fluids (1.5L extra/day reduces UTI 48% in RCT), vaginal estrogen (50% reduction in postmenopausal women), behavioral modifications. Reserve antibiotic prophylaxis for when these fail.

Principle 6: Surveillance and Audit Monitor local resistance patterns to guide empirical choices. In areas with > 20% E. coli trimethoprim resistance, switch first-line to nitrofurantoin. Track prescribing via audits to identify overprescribing.

Impact: Proper stewardship reduces antimicrobial resistance (currently 10-15% ESBL E. coli, 15-30% fluoroquinolone resistance), C. difficile, and healthcare costs, while maintaining treatment efficacy."

---

Question 6: "Describe your approach to a patient with recurrent UTI—three episodes in the past year."

Model Answer: "Recurrent UTI, defined as ≥3 episodes in 12 months or ≥2 in 6 months, warrants systematic evaluation to distinguish relapse from reinfection and identify modifiable risk factors.

Step 1: Confirm Diagnosis Review previous episodes—were they culture-proven or empirically treated? Symptoms consistent with UTI or potentially interstitial cystitis, STI, or other mimics? Obtain MSU culture during next symptomatic episode to confirm.

Step 2: Distinguish Relapse vs Reinfection

• Relapse: Same organism less than 2 weeks after treatment—suggests persistent focus like renal calculus, abscess, or prostatic focus in men. Requires imaging (renal ultrasound ± CT urogram) and prolonged antibiotics (4-6 weeks).
• Reinfection: Different organism or > 2 weeks—accounts for 80% of recurrent UTI. Managed with behavioral modifications and prophylaxis if needed.

Step 3: Identify Risk Factors

• Sexual activity: Frequency, post-coital voiding habits, spermicide use
• Menopausal status: Vaginal atrophy in postmenopausal women
• Voiding habits: Delayed voiding, incomplete emptying
• Fluid intake: Inadequate hydration
• Medical: Diabetes, immunosuppression, neurogenic bladder
• Structural (if relapse pattern): Stones, obstruction, VUR

Step 4: Non-Antimicrobial Prevention (first-line)

• Increase fluid intake: RCT evidence shows 1.5L extra water/day reduces UTI by 48%
• Post-coital voiding
• Avoid spermicides if applicable
• Vaginal estrogen if postmenopausal: Estriol cream 0.5mg twice weekly reduces rUTI by 50%
• Cranberry products: Weak evidence but low harm
• Void regularly, avoid prolonged holding

Step 5: Antimicrobial Prophylaxis (if non-antimicrobial strategies fail after 3-6 months)

• Continuous: Nitrofurantoin 50-100mg nocte for 6-12 months (reduces recurrence 80-95%)
• Post-coital: Single dose of nitrofurantoin or trimethoprim within 2 hours of intercourse (if intercourse-related)
• Alternative: Trimethoprim 100mg nocte (if local resistance low)
• Duration: 6-12 month trial, then discontinue and monitor

Step 6: Alternative Strategies

• Methenamine hippurate 1g BD: Non-antibiotic urinary antiseptic (converts to formaldehyde in acidic urine); modest efficacy
• D-Mannose: Limited RCT data; competitive FimH inhibitor
• Topical probiotics: Lactobacillus; conflicting evidence

Step 7: Specialist Referral (if refractory)

• Urology: Cystoscopy to exclude bladder pathology (interstitial cystitis, malignancy)
• Consider urodynamics if incomplete emptying suspected

This stepped approach balances symptom control, quality of life, and antimicrobial stewardship."

---

13. Patient/Layperson Explanation

What is a Urinary Tract Infection (UTI)?

A urinary tract infection is a bacterial infection affecting your urinary system—the kidneys, bladder, or the tube that carries urine from your bladder (urethra). UTIs are very common, especially in women, and usually easy to treat with antibiotics.

Two Main Types:

1. Bladder infection (cystitis): Infection in your bladder—the most common type
2. Kidney infection (pyelonephritis): Infection in one or both kidneys—more serious

What Causes UTI?

UTIs are caused by bacteria, most commonly E. coli (a bacterium normally found in your bowel), entering your urinary system. This usually happens when bacteria from the skin or bowel area travel up the urethra into the bladder.

Why Women Get UTI More Often:

• Women have a shorter urethra (the tube from bladder to outside), making it easier for bacteria to reach the bladder
• The opening of the urethra is close to the anus, where bacteria live
• Sexual activity can introduce bacteria
• Hormonal changes during menopause can increase risk

Other Risk Factors:

• Not drinking enough fluids
• Holding urine for long periods
• Pregnancy
• Diabetes
• Weakened immune system
• Urinary catheters

What are the Symptoms?

Bladder Infection (Cystitis) Symptoms:

• Burning or stinging when you pass urine (pee)
• Needing to pee frequently and urgently, even when you've just been
• Pain or discomfort in your lower tummy (below belly button)
• Cloudy, dark, or strong-smelling urine
• Sometimes blood in your urine
• No fever

Kidney Infection (Pyelonephritis) Symptoms:

• High temperature (fever) and feeling generally unwell
• Pain in your side or back (where kidneys are located)
• Feeling sick or being sick
• Shivering/shaking
• You may also have bladder infection symptoms

When to See a Doctor Urgently:

• High fever with back/side pain (possible kidney infection)
• Blood in your urine
• Vomiting and unable to keep down fluids
• Feeling very unwell or confused
• Symptoms not improving after 2-3 days of antibiotics
• If you're pregnant and have any UTI symptoms

How is UTI Diagnosed?

Bladder Infection: In healthy women with typical symptoms, your doctor can diagnose a bladder infection without tests and start treatment immediately.

Urine Test (if needed):

• Urine dipstick: Quick test on a sample of your urine to check for infection signs
• Urine culture: Sample sent to lab to identify which bacteria is causing infection and which antibiotics will work best
• Usually done if symptoms are severe, infection keeps coming back, or you're pregnant/male/have other health problems

Kidney Infection:

• Urine culture always recommended
• Blood tests to check how well your kidneys are working
• Sometimes a scan (ultrasound or CT) if infection is severe or not improving

How is UTI Treated?

Bladder Infection:

• Antibiotics: Usually a 3-day course of tablets
  • "Common antibiotics: Nitrofurantoin, Trimethoprim"
  • Take the full course even if you feel better
• Pain relief: Paracetamol or ibuprofen for discomfort
• Drink plenty of fluids: Water is best—helps flush bacteria out

Expected Improvement:

• Symptoms should start improving within 1-2 days
• If no better after 2-3 days, contact your doctor (you may need different antibiotics)

Kidney Infection:

• Antibiotics: Usually 7-14 days (longer than bladder infection)
• Mild cases: Tablets at home
• Severe cases: Admission to hospital for antibiotics through a drip (IV), fluids, and monitoring

Important: Complete the Antibiotic Course Stopping antibiotics early (when you feel better) can lead to infection returning or bacteria becoming resistant.

Can I Prevent UTI?

Lifestyle Measures:

• Drink plenty of fluids (6-8 glasses of water daily)—helps wash bacteria out
• Don't hold urine—go when you need to
• Pee after sex—helps flush out bacteria introduced during intercourse
• Wipe front to back after using the toilet (women)—prevents bacteria from bowel reaching urethra
• Avoid perfumed soaps, bubble baths, or vaginal douches around genital area—can irritate

If UTI Keeps Coming Back (Recurrent UTI):

Some women get frequent UTIs (3 or more per year). If this happens to you:

• Your doctor may suggest:
  • Vaginal estrogen cream (if you're post-menopausal)—helps restore natural defenses
  • Low-dose antibiotics taken daily or after sex to prevent infection
  • Cranberry products (juice or tablets)—may help some people, though evidence is mixed
  • Reviewing your contraception (diaphragm with spermicide increases UTI risk)

Special Situations

Pregnancy:

• UTI in pregnancy needs treatment even if you have no symptoms (to prevent kidney infection and preterm labor)
• All pregnant women have urine tested around 12-16 weeks
• Safe antibiotics are available during pregnancy

Men:

• UTI is less common in men—always requires investigation to find underlying cause (prostate problems, kidney stones)

Elderly:

• UTI symptoms may be different—confusion, falls, or just feeling unwell rather than typical urinary symptoms

Frequently Asked Questions

Q: Can I treat UTI without antibiotics? A: Mild bladder infections sometimes clear on their own, but antibiotics speed recovery and prevent complications. Kidney infections always need antibiotics.

Q: Do cranberry products work? A: Evidence is mixed. They may help prevent UTI in some people, but they don't treat an active infection.

Q: Is UTI contagious or sexually transmitted? A: No, UTI is not contagious or a sexually transmitted infection. However, sex can introduce bacteria into the urethra, increasing infection risk.

Q: Why do I keep getting UTI? A: Recurrent UTI is common in women. Risk factors include anatomy, sexual activity, menopause, and individual susceptibility. Your doctor can discuss prevention strategies.

Q: Can I have sex with a UTI? A: It's best to wait until symptoms resolve and you've finished antibiotics. Sex may worsen discomfort and introduce more bacteria.

Q: Will UTI damage my kidneys? A: Bladder infections don't usually cause kidney damage. Kidney infections can rarely cause scarring if severe or left untreated, but with prompt treatment, the outlook is excellent.

---

14. Key Takeaways

For Clinicians

1. Distinguish Lower from Upper UTI: Dysuria/frequency without fever = cystitis (3-day antibiotics, outpatient). Fever + loin pain = pyelonephritis (7-14 day antibiotics, consider admission). Misclassification risks urosepsis.

2. UTI in Men is Always Complicated: Investigate for prostatic disease, stones, stricture. First episode warrants renal imaging (ultrasound).

3. Antimicrobial Stewardship is Critical: Use narrow-spectrum agents (nitrofurantoin, trimethoprim) for uncomplicated cystitis; 3-day courses are as effective as longer; avoid treating asymptomatic bacteriuria except in pregnancy and pre-urological procedures.

4. Pregnancy Screening Prevents Pyelonephritis: Screen all pregnant women for ASB at 12-16 weeks; treat to prevent pyelonephritis (20-40% if untreated) and preterm labor.

5. Recurrent UTI Requires Systematic Approach: Distinguish relapse (same organism less than 2 weeks → investigate for focus) from reinfection (different organism → behavioral modifications ± prophylaxis). Non-antimicrobial strategies (vaginal estrogen in postmenopausal women, increased fluids) are first-line.

6. Urosepsis Recognition Saves Lives: UTI is a leading cause of sepsis. SIRS criteria (fever, tachycardia, hypotension, altered mental status) mandate urgent IV antibiotics, fluids, and blood cultures within 1 hour.

7. Imaging for Persistent Fever: Pyelonephritis not improving at 48-72 hours requires CT to exclude abscess or obstruction.

For Medical Students/Trainees

1. E. coli Dominates: Accounts for 75-95% of community-acquired UTI. Virulence factors (type 1 fimbriae for bladder, P fimbriae for kidneys) determine anatomical site.

2. Clinical Diagnosis Sufficient for Uncomplicated Cystitis: Dysuria + frequency without vaginal symptoms in healthy women = 90% UTI probability. Urine culture not routinely needed; empirical treatment appropriate.

3. Know When to Culture: Send MSU before antibiotics in: men, pregnancy, pyelonephritis, catheterized, immunocompromised, recurrent UTI, treatment failure.

4. Dipstick Interpretation: Nitrites (high specificity 90-95% for UTI) + leukocytes (moderate sensitivity 75-85%) combined improves accuracy. Negative dipstick reduces UTI probability to less than 20%.

5. Fluoroquinolones are NOT First-Line: Reserve ciprofloxacin for pyelonephritis or culture-proven resistant organisms. Overuse drives resistance, C. difficile, and adverse effects.

6. Asymptomatic Bacteriuria ≠ UTI: Treat only in pregnancy and pre-urological procedures. Do not treat in elderly, diabetic, or catheterized patients—no benefit, drives resistance.

For Patients

1. Bladder Infection Symptoms: Burning on peeing, needing to pee often and urgently, lower tummy pain—see your doctor for antibiotics.

2. Kidney Infection Symptoms: Fever + back/side pain + feeling very unwell—see a doctor urgently (may need hospital treatment).

3. Finish Your Antibiotics: Even if you feel better, complete the full course to prevent infection returning or bacteria becoming resistant.

4. Prevention: Drink plenty of water, don't hold urine, pee after sex, wipe front-to-back.

5. Recurrent UTI Help Available: If you get 3+ UTI per year, speak to your doctor about prevention strategies (vaginal estrogen, low-dose antibiotics).

6. Pregnancy: All pregnant women are tested for UTI even without symptoms—untreated infection can cause serious complications.

---

15. References

1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284. doi:10.1038/nrmicro3432

2. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13. doi:10.1016/j.idc.2013.09.003

3. National Institute for Health and Care Excellence. Urinary tract infection (lower): antimicrobial prescribing (NG109). 2018. https://www.nice.org.uk/guidance/ng109

4. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis. 2015;15:545. doi:10.1186/s12879-015-1282-4

5. Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ. 2013;346:f3140. doi:10.1136/bmj.f3140

6. Albert X, Huertas I, Pereiro II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209. doi:10.1002/14651858.CD001209.pub2

7. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2019;11(11):CD000490. doi:10.1002/14651858.CD000490.pub4

8. Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121

9. Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev. 2005;(2):CD004682. doi:10.1002/14651858.CD004682.pub2

10. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-756. doi:10.1056/NEJM199309093291102

11. Fihn SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol. 1996;144(5):512-520. doi:10.1093/oxfordjournals.aje.a008958

12. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142(1):20-27. doi:10.7326/0003-4819-142-1-200501040-00008

13. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA; Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010;31(4):319-326. doi:10.1086/651091

14. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69(7):4572-4579. doi:10.1128/IAI.69.7.4572-4579.2001

15. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002;287(20):2701-2710. doi:10.1001/jama.287.20.2701

16. Devillé WL, Yzermans JC, van Duijn NP, Bezemer PD, van der Windt DA, Bouter LM. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol. 2004;4:4. doi:10.1186/1471-2490-4-4

17. Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982;307(8):463-468. doi:10.1056/NEJM198208193070802

18. Borofsky MS, Walter D, Shah O, Goldfarb DS, Mues AC, Makarov DV. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. J Urol. 2013;189(3):946-951. doi:10.1016/j.juro.2012.09.088

19. Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509-1515. doi:10.1001/jamainternmed.2018.4204

20. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD001321. doi:10.1002/14651858.CD001321.pub5

21. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af

---

---

Medical Disclaimer: This content is for educational purposes and clinical reference. Always consult current local guidelines, antimicrobial susceptibility patterns, and specialist advice for individual patient management. MedVellum content does not replace clinical judgment or established protocols.